NCT00800644 is a clinical trial of CT or MRI + Blood Test in Cervical Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00800644?

NCT00800644 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00800644?

Interventions in NCT00800644: CT or MRI + Blood Test.

What condition does NCT00800644 study?

NCT00800644 studies Cervical Cancer, Endometrial Cancer, Vaginal Cancer.

Is NCT00800644 still recruiting?

NCT00800644 is currently status unknown. Last updated 13 January 2020.

Last reviewed 2020-01-13 · How we verify

NCT00800644

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pelvic Fractures and Radiation Therapy for Cervical Cancer

Status unknown Last updated 13 January 2020

What this trial tests

trial testing CT or MRI + Blood Test in Cervical Cancer in 239 participants. Status unknown.

Timeline

5 November 2008

Primary endpoint
30 November 2020

30 November 2020

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	239
Start date	5 November 2008
Primary completion	30 November 2020
Estimated completion	30 November 2020
Sites	1 location across United States

Drugs / interventions tested

CT or MRI + Blood Test

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Endometrial Cancer — all drugs for Endometrial Cancer →
Vaginal Cancer — all drugs for Vaginal Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, female only, with Cervical Cancer or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to estimate how often pelvic fractures occur in women treated with radiation therapy for either newly diagnosed or recurrent cervical, endometrial, or vaginal cancer. The study will also estimate the changes in bone mineral density and the changes in the blood that relate to "bone turnover". High bone turnover can weaken bones and make you more likely to break a bone.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women.
Salcedo MP, Sood AK, Jhingran A, Eifel PJ, et al · · 2020 · cited 35× · PMID 32125711 · DOI 10.1002/cncr.32807

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00800644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 13 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00800644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing